Evidence map›Paper›PMID 38041476›Full record

ArticleHuman brain mapping2024

Comparison of automated and manual quantification methods for neuromelanin-sensitive MRI in Parkinson's disease.

Nicholas Shaff, Erik Erhardt, Stephanie Nitschke, Kayla Julio, Christopher Wertz, Andrei Vakhtin, Arvind Caprihan, Gerson Suarez-Cedeno, Amanda Deligtisch, Sarah Pirio Richardson and 2 more

Open access · goldAbstract read
In one paragraph

Article in Human brain mapping, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Parkinson's disease cerebrovascular reactivity pattern: A feasibility study.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Nicholas ShaffThe Mind Research Network, Albuquerque, New Mexico, USA.
Erik ErhardtDepartment of Mathematics and Statistics, University of New Mexico, Albuquerque, New Mexico, USA.
Stephanie NitschkeThe Mind Research Network, Albuquerque, New Mexico, USA.
Kayla JulioThe Mind Research Network, Albuquerque, New Mexico, USA.
Christopher WertzThe Mind Research Network, Albuquerque, New Mexico, USA.
Andrei VakhtinThe Mind Research Network, Albuquerque, New Mexico, USA.
Arvind CaprihanThe Mind Research Network, Albuquerque, New Mexico, USA.
Gerson Suarez-CedenoNene and Jamie Koch Comprehensive Movement Disorder Center, Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA.
Amanda DeligtischNene and Jamie Koch Comprehensive Movement Disorder Center, Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA.
Sarah Pirio RichardsonNene and Jamie Koch Comprehensive Movement Disorder Center, Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA.
Andrew R MayerThe Mind Research Network, Albuquerque, New Mexico, USA.ORCID 0000-0003-2396-5609
Sephira G RymanThe Mind Research Network, Albuquerque, New Mexico, USA.ORCID 0000-0002-1758-3391
Mind Research Network · USUniversity of New Mexico · US

Funding

The Impact of Diffuse Mild Brain Injury on Clinical Outcomes in ChildrenR01NS098494 · NINDS · THE MIND RESEARCH NETWORK · PI Andrew Robert Mayer · 2016 to 2026
$7.6M
Pilot Project Program (PPP)P30GM122734 · NIGMS · THE MIND RESEARCH NETWORK · PI MAYER, ANDREW ROBERT · 2018 to 2022
$7.0M
Validation of Biomarkers of Small Vessel Injury in VCIDUF1NS100598 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2021 to 2023
$6.3M
MRI and CSF Biomarkers of White Matter Injury in VCIDUH3NS100598 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2018 to 2020
$3.3M
Microbiome-gut-brain dysfunction in prodromal and symptomatic Lewy body diseasesR01NS133569 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Sephira Ryman · 2023 to 2026
$3.2M
Scientific CoreP20AG068077 · NIA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BHASKAR, KIRAN · 2020 to 2022
$3.1M
Cognitive sequelae of cerebrovascular and gut dysfunction in post-acute COVID-19 syndrome.R01NS129407 · NINDS · LOVELACE BIOMEDICAL RESEARCH INSTITUTE · PI Andrei A Vakhtin · 2023 to 2026
$2.9M
MRI and CSF Biomarkers of White Matter Injury in VCIDUH2NS100598 · NINDS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ROSENBERG, GARY ALLEN · 2016 to 2017
$2.1M
Electroconvulsive therapy amplitude titration for improved clinical outcomes in late-life depressionR61MH125126 · NIMH · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI ABBOTT, CHRISTOPHER C · 2021 to 2022
$1.4M
Cerebrovascular contributions to cognitive impairment in Lewy body dementiasR03AG075408 · NIA · LOVELACE BIOMEDICAL RESEARCH INSTITUTE · PI RYMAN, SEPHIRA · 2022 to 2023
$362k
NIA NIH HHS P20 AG068077NIA NIH HHS R03 AG075408NIGMS NIH HHS P30 GM122734NIH HHS 1P30GM122734-01NIH HHS 1R61MH125126-01NIH HHS 2UF1NS100598-06NIH HHS 5R01NS098494-05NIH HHS NS100598NIH HHS NS129407-01A1NIH HHS P20AG068077NIH HHS P20-AG068077-01NIH HHS P30 GM122734NIH HHS R01NS133569NIH HHS R03AG075408NIH HHS R61 MH125126NIH HHS UH3 NS100598NIMH NIH HHS R61 MH125126NINDS NIH HHS R01 NS098494NINDS NIH HHS R01 NS129407NINDS NIH HHS R01 NS133569NINDS NIH HHS UF1 NS100598NINDS NIH HHS UH2 NS100598NINDS NIH HHS UH3 NS100598
6 · The paper itself

Abstract

Neuromelanin-sensitive magnetic resonance imaging quantitative analysis methods have provided promising biomarkers that can noninvasively quantify degeneration of the substantia nigra in patients with Parkinson's disease. However, there is a need to systematically evaluate the performance of manual and automated quantification approaches. We evaluate whether spatial, signal-intensity, or subject specific abnormality measures using either atlas based or manually traced identification of the substantia nigra better differentiate patients with Parkinson's disease from healthy controls using logistic regression models and receiver operating characteristics. Inference was performed using bootstrap analyses to calculate 95% confidence interval bounds. Pairwise comparisons were performed by generating 10,000 permutations, refitting the models, and calculating a paired difference between metrics. Thirty-one patients with Parkinson's disease and 22 healthy controls were included in the analyses. Signal intensity measures significantly outperformed spatial and subject specific abnormality measures, with the top performers exhibiting excellent ability to differentiate patients with Parkinson's disease and healthy controls (balanced accuracy = 0.89; area under the curve = 0.81; sensitivity =0.86; and specificity = 0.83). Atlas identified substantia nigra metrics performed significantly better than manual tracing metrics. These results provide clear support for the use of automated signal intensity metrics and additional recommendations. Future work is necessary to evaluate whether the same metrics can best differentiate atypical parkinsonism, perform similarly in de novo and mid-stage cohorts, and serve as longitudinal monitoring biomarkers.

Indexed as

MelaninsParkinson DiseaseBiomarkersHumansMagnetic Resonance ImagingSensitivity and SpecificitySubstantia NigraBiomarkersMelaninsneuromelaninneuromelanin sensitive MRIParkinson's disease

Identifiers

PMID38041476
PMCPMC10789205
OpenAlexW4389265241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.